Towards New Delivery Agents for Boron Neutron Capture Therapy: Synthesis and In Vitro Evaluation of a Set of Fluorinated Carbohydrate Derivatives.

boron neutron capture therapy cancer therapeutics carbohydrates chemical synthesis preclinical profiling structural elucidation

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
09 Sep 2024
Historique:
received: 17 07 2024
revised: 21 08 2024
accepted: 24 08 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 14 9 2024
Statut: epublish

Résumé

Boron Neutron Capture Therapy (BNCT) is a cancer treatment which combines tumor-selective boron delivery agents with thermal neutrons in order to selectively eradicate cancer cells. In this work, we focus on the early-stage development of carbohydrate delivery agents for BNCT. In more detail, we expand upon our previous GLUT-targeting approach by synthesizing and evaluating the potential embedded in a representative set of fluorinated carbohydrates bearing a boron cluster. Our findings indicate that these species may have advantages over the boron delivery agents in current clinical use, e.g., significantly improved boron delivery capacity at the cellular level. Simultaneously, the carbohydrate delivery agents were found to bind strongly to plasma proteins, which may be a concern requiring further action before progression to in vivo studies. Altogether, this work brings new insights into factors which need to be accounted for if attempting to develop theranostic agents for BNCT based on carbohydrates in the future.

Identifiants

pubmed: 39275111
pii: molecules29174263
doi: 10.3390/molecules29174263
pii:
doi:

Substances chimiques

Carbohydrates 0
Boron N9E3X5056Q

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Jane and Aatos Erkko Foundation
Organisme : Research Council of Finland
Organisme : Syöpäsäätiö
Organisme : Ruth and Nils-Erik Stenbäck foundation
Organisme : University of Helsinki
Organisme : Deerfield Management Company L.P.
Organisme : Aviko Radiopharmaceuticals Inc.

Auteurs

Jelena Matović (J)

Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.

Juulia Järvinen (J)

School of Pharmacy, University of Eastern Finland, FI-70211 Kuopio, Finland.

Iris K Sokka (IK)

Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.

Surachet Imlimthan (S)

Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.

Olli Aitio (O)

Glykos Finland Ltd., FI-00790 Helsinki, Finland.

Mirkka Sarparanta (M)

Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.

Jarkko Rautio (J)

School of Pharmacy, University of Eastern Finland, FI-70211 Kuopio, Finland.

Filip S Ekholm (FS)

Department of Chemistry, University of Helsinki, FI-00014 Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH